Keros amends lease for 35,662 sq ft in Lexington; 8-year term, base rent $202K/mo

Keros Therapeutics, Inc.

Phase A (31,991 sq ft) delivered Jan 4, 2023; Phase B (3,671 sq ft vivarium) due by May 1, 2023.
Base rent starts earlier of 8 months post Phase B or 11 months post Phase A delivery.
Initial monthly base rent $202,084.66, escalating ~3% annually.
Lease term is 8 years from Phase A commencement.
Landlord is Revolution Labs Owner, LLC; premises at 1050 Waltham St, Lexington, MA.

item 1.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Keros Therapeutics, Inc. amended Lease Amendment with Revolution Labs Owner, LLC (effective 2023-01-06).

Action: amendment
Agreement: lease
Counterparty: Revolution Labs Owner, LLC
Effective: 2023-01-06

Exact text from the filing

On January 6, 2023, Keros Therapeutics, Inc. (the “Company”) entered into a first amendment (the “Lease Amendment”) to that certain indenture of lease, dated September 7, 2021 (as amended, the “Lease”) with Revolution Labs Owner, LLC, a Delaware limited liability company (the “Landlord”), with respect to the Company’s office and laboratory space consisting of approximately 35,662 square feet located at 1050 Waltham Street, Lexington, Massachusetts (the “Premises”).

View on SEC.gov

Browse all material agreements →

Keros Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001664710-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.